Potential role of fecal microbiota in patients with constipation

From BugSigDB
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI Uniform resource identifier for web resources.
Authors
Tian Y, Zuo L, Guo Q, Li J, Hu Z, Zhao K, Li C, Li X, Zhou J, Zhou Y, Li XA
Journal
Therapeutic advances in gastroenterology
Year
2020
Keywords:
chronic functional constipation, fecal microbiota transplantation, gastrointestinal motility, intestinal flora
BACKGROUND: We evaluated the safety and efficacy of fecal microbiota transplantation (FMT) for chronic functional constipation (CFC) ineffectively treated by conventional constipation medication. METHODS: Thirty-four patients with CFC underwent FMT treatment (three rounds, via gastroscopy). Clinical scales, including the Wexner constipation score as the main index of efficiency, were completed at baseline; after each treatment, and at 2 and 3 months of follow up. Secondary evaluation indices included the self-assessment of constipation symptoms, patient assessment constipation quality-of-life questionnaire, Bristol stool form scale, and Zung's self-rating depression and anxiety scales. Gastrointestinal motility, motilin, gastrin, nitric oxide (NO), and 5-hydroxytryptamine (5-HT) were assessed before and after treatment. Intestinal flora changes were assessed by 16S ribosomal ribonucleic acid (rRNA) sequencing. RESULTS: There were no serious adverse reactions. The clinical cure rate was 73.5% (25/34), clinical remission rate was 14.7% (5/34), and the inefficiency rate was 11.8% (4/34). Clinical scale data indicated that the FMT treatment was effective. Furthermore, FMT treatment promoted intestinal peristalsis, increased gastrointestinal motility, and increased serum NO and 5-HT levels. The 16S rRNA sequencing data indicated that high abundances of Bacteroides, Klebsiella, Megamonas, Erysipelotrichaceae and Epulopiscium may be the cause of constipation, and high abundances of Prevotella, Acidaminococcus and Butyricimonas may be the main factors in curing constipation. CONCLUSION: Treatment with FMT regulates the intestinal microflora and changes the abundance of CFC-associated bacterial flora to improve constipation.

Experiment 1


Reviewed Marked as Reviewed by KateRasheed on 2025-6-11

Curated date: 2025/04/19

Curator: Inisimeon

Revision editor(s): Inisimeon, MyleeeA

Subjects

Location of subjects
China
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Transplant outcome measurement Transplant outcome measurement,transplant outcome measurement
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Before treatment, After 1st treatment, After 2nd treatment, After 3rd treatment, 2 month follow-up and 3 month follow up
Group 1 name Corresponds to the case (exposed) group for case-control studies
Donor
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
The donors were healthy individuals without diseases or pathologic conditions potentially associated with changes in the gut microbiota.
Group 0 sample size Number of subjects in the control (unexposed) group
34
Group 1 sample size Number of subjects in the case (exposed) group
4
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
1 month

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
Not specified

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
LEfSe
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
No
LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
2


Signature 1

Reviewed Marked as Reviewed by KateRasheed on 2025-6-11

Curated date: 2025/05/04

Curator: MyleeeA

Revision editor(s): MyleeeA

Source: Figure 5

Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between Donor versus Before treatment, After 1st treatment, After 2nd treatment, After 3rd treatment, 2 month follow-up and 3 month follow up.

Abundance in Group 1: increased abundance in Donor

NCBI Quality ControlLinks
Xanthobacteraceae
Asticcacaulis
Faecalibacterium
Dorea
Blautia
Anaerostipes
Lachnospiraceae
Oscillospiraceae

Revision editor(s): MyleeeA

Experiment 2


Reviewed Marked as Reviewed by KateRasheed on 2025-6-11

Curated date: 2025/05/01

Curator: MyleeeA

Revision editor(s): MyleeeA

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies
Donor, After 1st treatment, After 2nd treatment, After 3rd treatment, 2 month follow-up and 3 month follow up
Group 1 name Corresponds to the case (exposed) group for case-control studies
Before treatment
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients with chronic functional constipation before Fecal microbiota transplantation treatment.
Group 0 sample size Number of subjects in the control (unexposed) group
Not specified
Group 1 sample size Number of subjects in the case (exposed) group
Not specified

Lab analysis

Statistical Analysis

Signature 1

Reviewed Marked as Reviewed by KateRasheed on 2025-6-11

Curated date: 2025/05/04

Curator: MyleeeA

Revision editor(s): MyleeeA

Source: Figure 5

Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between Before treatment versus Donor, After 1st treatment, After 2nd treatment, After 3rd treatment, 2 month follow-up and 3 month follow up.

Abundance in Group 1: increased abundance in Before treatment

NCBI Quality ControlLinks
Phascolarctobacterium
Bacteroides

Revision editor(s): MyleeeA

Experiment 3


Reviewed Marked as Reviewed by KateRasheed on 2025-6-11

Curated date: 2025/05/01

Curator: MyleeeA

Revision editor(s): MyleeeA

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies
Donor, Before treatment, After 2nd treatment, After 3rd treatment, 2 month follow-up and 3 month follow up
Group 1 name Corresponds to the case (exposed) group for case-control studies
After 1st treatment
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients with chronic functional constipation after first treatment with Fecal microbiota transplantation.

Lab analysis

Statistical Analysis

Signature 1

Reviewed Marked as Reviewed by KateRasheed on 2025-6-11

Curated date: 2025/05/04

Curator: MyleeeA

Revision editor(s): MyleeeA

Source: Figure 5

Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between After 1st treatment versus Donor, Before treatment, After 2nd treatment, After 3rd treatment, 2 month follow-up and 3 month follow up.

Abundance in Group 1: increased abundance in After 1st treatment

NCBI Quality ControlLinks
Odoribacter

Revision editor(s): MyleeeA

Experiment 4


Reviewed Marked as Reviewed by KateRasheed on 2025-6-11

Curated date: 2025/05/01

Curator: MyleeeA

Revision editor(s): MyleeeA

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies
Donor, Before treatment, After 1st treatment, After 3rd treatment, 2 month follow-up and 3 month follow up
Group 1 name Corresponds to the case (exposed) group for case-control studies
After 2nd treatment
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients with chronic functional constipation after second treatment with Fecal microbiota transplantation.

Lab analysis

Statistical Analysis

Signature 1

Reviewed Marked as Reviewed by KateRasheed on 2025-6-11

Curated date: 2025/05/04

Curator: MyleeeA

Revision editor(s): MyleeeA

Source: Figure 5

Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between After 2nd treatment versus Donor, Before treatment, After 1st treatment, After 3rd treatment, 2 month follow-up and 3 month follow up.

Abundance in Group 1: increased abundance in After 2nd treatment

NCBI Quality ControlLinks
Bilophila

Revision editor(s): MyleeeA

Experiment 5


Reviewed Marked as Reviewed by KateRasheed on 2025-6-11

Curated date: 2025/06/09

Curator: Anne-mariesharp

Revision editor(s): Anne-mariesharp

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies
Donor, Before treatment, After 1st treatment, After 2nd treatment, 2-month follow up and 3-month follow up
Group 1 name Corresponds to the case (exposed) group for case-control studies
After 3rd treatment
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients with chronic functional constipation after third treatment with Fecal microbiota transplantation.

Lab analysis

Statistical Analysis

Signature 1

Reviewed Marked as Reviewed by KateRasheed on 2025-6-11

Curated date: 2025/06/09

Curator: Anne-mariesharp

Revision editor(s): Anne-mariesharp

Source: Figure 5

Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between After 3rd treatment versus Donor, Before treatment, After 1st treatment, After 2nd treatment, 2-month follow up and 3-month follow up.

Abundance in Group 1: increased abundance in After 3rd treatment

NCBI Quality ControlLinks
Dialister
Megamonas

Revision editor(s): Anne-mariesharp

Experiment 6


Reviewed Marked as Reviewed by KateRasheed on 2025-6-11

Curated date: 2025/06/09

Curator: Anne-mariesharp

Revision editor(s): Anne-mariesharp

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies
Donor, Before treatment, After 1st treatment, After 2nd treatment, After 3rd treatment and 3-month follow up
Group 1 name Corresponds to the case (exposed) group for case-control studies
2-month follow up
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients with chronic functional constipation after treatment with Fecal microbiota transplantation and at 2-months of follow up

Lab analysis

Statistical Analysis

Signature 1

Reviewed Marked as Reviewed by KateRasheed on 2025-6-11

Curated date: 2025/06/09

Curator: Anne-mariesharp

Revision editor(s): Anne-mariesharp

Source: Figure 5

Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between 2-month follow up versus Donor, Before treatment, After 1st treatment, After 2nd treatment, After 3rd treatment and 3-month follow up.

Abundance in Group 1: increased abundance in 2-month follow up

NCBI Quality ControlLinks
Acidaminococcus
Butyricimonas

Revision editor(s): Anne-mariesharp

Experiment 7


Reviewed Marked as Reviewed by KateRasheed on 2025-6-11

Curated date: 2025/06/09

Curator: Anne-mariesharp

Revision editor(s): Anne-mariesharp

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies
Donor, Before treatment, After 1st treatment, After 2nd treatment, After 3rd treatment and 2-month follow up
Group 1 name Corresponds to the case (exposed) group for case-control studies
3-month follow up
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients with chronic functional constipation after treatment with Fecal microbiota transplantation and at 3-months of follow up

Lab analysis

Statistical Analysis

Signature 1

Reviewed Marked as Reviewed by KateRasheed on 2025-6-11

Curated date: 2025/06/09

Curator: Anne-mariesharp

Revision editor(s): Anne-mariesharp

Source: Figure 5

Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between 3-month follow up versus Donor, Before treatment, After 1st treatment, After 2nd treatment, After 3rd treatment and 2-month follow up.

Abundance in Group 1: increased abundance in 3-month follow up

NCBI Quality ControlLinks
Acinetobacter
Desulfobulbaceae
Geodermatophilus
Kingella
Luteimonas
Pleomorphomonas
Synechococcus
Thalassospira
Xenococcaceae
ASSO_13ASSO_13
mle1_48mle1_48

Revision editor(s): Anne-mariesharp